The phenomenon at the center of the study is the Warburg effect, a metabolic behavior first described nearly a century ago. Even when oxygen is available, many cancer cells rely heavily on glycolysis—the stepwise breakdown of glucose in the cell’s cytoplasm—and convert much of the resulting pyruvate into lactate. This is less efficient than mitochondrial oxidative phosphorylation in terms of ATP produced per molecule of glucose, but it can provide rapidly dividing cells with metabolic intermediates needed to build DNA, proteins and membranes. Glycolysis also allows cells to maintain energy production under fluctuating oxygen conditions. In breast cancer, the degree to which this metabolic program is engaged has been associated with disease behavior and patient outcomes, but the molecular switches that connect glycolysis to the cell’s transcriptional machinery have remained incompletely understood.

The investigators focused on AKR1B10, an enzyme involved in cellular metabolism whose abnormal overexpression has been observed in cancer. Enzymes of this kind can influence the balance of aldehydes, carbonyl compounds and other metabolic molecules, but AKR1B10’s precise relationship with glucose metabolism in breast cancer was unclear. To investigate it, the team combined bioinformatics with analyses of breast-cancer tissues and cell lines, measuring gene and protein activity using quantitative reverse-transcription polymerase chain reaction and western blotting. They also used metabolomics to survey changes in small molecules, glucose-metabolism assays to track the behavior of cancer cells, and mass spectrometry to examine protein modifications. This multi-layered approach allowed the researchers to follow the pathway from AKR1B10 expression to metabolic output and, ultimately, cell proliferation.

The experiments indicated that AKR1B10 is not simply correlated with aggressive cancer-cell behavior but is functionally important for it. When researchers reduced AKR1B10 activity, breast-cancer cells showed impaired glycolysis and reduced proliferation. Conversely, experiments designed to increase its activity supported the metabolic and growth-associated phenotype. The researchers tested these gain- and loss-of-function effects both in cultured cells and in animal models, providing evidence beyond a single laboratory system. Their results identified elevated AKR1B10 as a driver of the Warburg effect in the models examined, with increased glucose use and lactate generation accompanying the enzyme’s overexpression. The findings do not establish that AKR1B10 alone determines the course of human breast cancer, but they place the protein at a critical control point within the tumor’s metabolic network.

The mechanistic breakthrough came when the team examined how AKR1B10 communicates with other proteins. The study found that AKR1B10 acts as a molecular bridge between IGF2R and PGK1. IGF2R is a receptor involved in the trafficking and handling of insulin-like growth factor 2, while PGK1 catalyzes a reversible step in glycolysis, transferring a phosphate group from 1,3-bisphosphoglycerate to ADP and generating ATP. According to the researchers, the AKR1B10-linked interaction enables IGF2R to promote phosphorylation of PGK1 at the amino-acid position tyrosine 324, designated Y324. Phosphorylation can alter a protein’s activity, location or interactions, and in this case the modification appears to push PGK1 toward a state that supports stronger glycolytic flux. The resulting rise in lactate becomes the signal for the next stage of the cascade.

Lactate is often treated as a metabolic waste product, the acidic end point of glycolysis that must be exported from cells. Increasing evidence, however, shows that it can also act as a signaling molecule and a source of chemical groups used to modify proteins. The study links the lactate produced through the AKR1B10–IGF2R–PGK1 circuit to a process called histone lactylation. Histones are proteins around which DNA is wrapped, and chemical marks on histones can make particular genomic regions more or less accessible to transcriptional machinery. The researchers detected dynamic lactylation at lysine 12 of histone H4, referred to as H4K12la. In effect, the cancer cell’s altered metabolism appears to leave a chemical imprint on its chromatin. This provides a direct route by which excess glycolysis can influence gene expression rather than merely supplying energy.

The researchers then used RNA sequencing and chromatin immunoprecipitation sequencing to determine which genes were affected by this metabolic-to-epigenetic connection. Their results implicated transcriptional activation of mTOR, a master regulator of cell growth, protein synthesis, nutrient sensing and survival. The mechanistic sequence proposed by the study is therefore unusually long but tightly connected: increased AKR1B10 supports an interaction involving IGF2R and PGK1; IGF2R-dependent phosphorylation activates PGK1; enhanced PGK1 activity increases glycolysis and lactate production; lactate promotes H4K12 lactylation; and this chromatin modification helps activate mTOR transcription. Once engaged, mTOR signaling can encourage the synthesis of cellular components and the growth programs required for proliferation. The pathway illustrates how cancer metabolism and gene regulation can operate as a feedback system, with a biochemical change in the cytoplasm reshaping activity in the nucleus.

The therapeutic experiments offered an early test of whether this pathway could be disrupted. Knockdown of AKR1B10 suppressed the signaling axis and reprogrammed the metabolism of breast-cancer cells, reducing their proliferative capacity. The researchers also examined oleanolic acid, or OA, as an AKR1B10 inhibitor in combination with 2-deoxy-D-glucose, a glycolysis inhibitor commonly abbreviated 2-DG. The combination inhibited the AKR1B10-centered pathway more effectively in the reported experiments than leaving the metabolic circuit unchallenged, while also restraining cell proliferation. The logic behind the pairing is complementary: blocking AKR1B10 may weaken the upstream molecular bridge, while 2-DG limits glucose breakdown itself. Together, the compounds could attack both the regulatory trigger and the metabolic output. However, these findings remain preclinical. The study does not show that OA and 2-DG are safe or effective treatments for patients, nor does it establish how the proposed strategy would interact with standard breast-cancer therapies.

The work also highlights why metabolic targets can be difficult to translate into medicines. Glycolysis and mTOR signaling are used by healthy cells as well as tumors, so inhibiting them broadly could produce toxicity or affect immune, muscle and other tissues. AKR1B10 may offer a more selective point of intervention if its overexpression or pathway activity distinguishes particular breast-cancer subtypes, but that possibility will require detailed validation in larger patient cohorts. The study used clinical tissue samples collected with informed consent and approvals from institutional ethics committees, along with animal experiments conducted under approved guidelines. Even so, questions remain about which molecular breast-cancer subtypes depend most strongly on the pathway, whether tumors can bypass it through alternative glycolytic enzymes, and whether resistance emerges after prolonged treatment. Future studies will need to test the biomarkers that could identify responsive tumors and assess the pathway in clinically relevant treatment settings.

The significance of the findings lies less in presenting an immediate cancer cure than in revealing a form of molecular entanglement that may help tumors thrive. AKR1B10 appears to connect a metabolic enzyme, a receptor, a glycolytic catalyst, a histone modification and a growth pathway into one circuit. That architecture helps explain how breast-cancer cells can convert their demand for glucose into a durable proliferative advantage: nutrients are processed into lactate, lactate modifies chromatin, and chromatin activates signals that support further growth. By combining metabolic inhibition with targeted disruption of this signaling axis, researchers may eventually be able to interrupt the feedback loop at several points. For now, the study provides a mechanistic blueprint—and a potentially shareable target—for understanding why some breast tumors are so metabolically aggressive.

Lactate was traditionally considered metabolic waste formed during anaerobic glycolysis, particularly abundant in the hypoxic microenvironment of tumors. However, recent evidence, as thoroughly compiled in this review, positions lactate as a metabolic sentinel capable of remodeling chromatin architecture through lactylation — the covalent attachment of lactyl groups to lysine residues on histones and other proteins. This epigenetic modification alters gene expression patterns and contributes to oncogenic reprogramming that underpins lung cancer malignancy.

The review delineates a sophisticated “reflex arc” regulatory framework for lactylation dynamics. Specific enzymes termed “writers,” including the acetyltransferase p300 and aminoacyl-tRNA synthetases AARS1 and AARS2, are responsible for sensing intracellular lactate levels and catalyzing the addition of lactyl groups to target proteins. Conversely, “eraser” enzymes such as various histone deacetylases (HDACs) and sirtuins (SIRT1 and SIRT3) remove these lactyl modifications, thus enabling a dynamic and reversible regulatory system. The “readers,” notably the chromatin remodeler BRG1, recognize lactyl marks and modulate downstream transcriptional programs essential for tumor growth and adaptation.

Within lung cancer pathology, histone H3 lactylation at lysine 18 (H3K18la) emerges as a pivotal epigenetic signal promoting immune evasion. In non-small cell lung cancer (NSCLC), this modification activates the POM121/MYC/PD-L1 axis, facilitating immune checkpoint upregulation that allows tumor cells to subvert cytotoxic T cell responses. In small cell lung cancer (SCLC), a distinct mechanistic pathway involving LDH-mediated H3K18 lactylation influences the Nur77 nuclear receptor, further sculpting cell fate decisions toward resistance and survival.

The authors emphasize the presence of self-reinforcing feedback loops that sustain oncogenic lactylation signaling. For instance, the CTHRC1 (collagen triple helix repeat containing 1) protein amplifies glycolytic flux and H3K18 lactylation, creating a metabolic-epigenetic cycle that perpetuates therapeutic resistance. Another intricate loop involving nicotinamide N-methyltransferase (NNMT), early growth response 1 (EGR1), and lactate production stabilizes an environment conducive to acquired resistance against epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), a mainstay treatment for certain lung cancers.

This insight into lactylation as a metabolic-epigenetic nexus offers profound therapeutic implications. Targeting the enzymes responsible for lactyl mark deposition or removal presents an opportunity to reprogram tumor epigenetic states and reverse deleterious drug resistance phenotypes. Strategies that reduce lactate accumulation—either by inhibiting glycolytic enzymes or modulating tumor microenvironment acidity—may further disrupt lactylation-driven pathways, restoring sensitivity to existing treatments.

Yong Xu and colleagues advocate for integrating this novel lactylation paradigm into precision oncology frameworks. By designing therapies that specifically intercept lactylation writers, readers, or erasers, it may be possible to dismantle the molecular circuitry that empowers lung cancer cells to circumvent standard therapies. Such approaches could potentiate efficacy, delay relapse, and improve patient survival outcomes.

Furthermore, the review calls for intensified research into the nuanced interplay between metabolic rewiring and epigenetic modifications in cancer. Understanding how lactylation interfaces with other histone modifications and transcription factor networks will be vital to fully exploit this axis. The dynamic regulatory milieu uncovered here underscores cancer’s remarkable plasticity and the necessity for multi-modal treatment strategies.

As the role of lactate as an epigenetic modulator gains prominence, it challenges prior dogmas regarding metabolic byproducts in oncology. This review not only reframes lactate as a driver of malignancy but also spotlights the broader implications for tumor immunology and metabolic crosstalk within the tumor microenvironment.

In summary, the findings compiled by Xu’s team constitute a pivotal step toward unraveling the complex molecular architecture of lung cancer resistance mechanisms. By illuminating the centrality of lactylation in integrating metabolic signals with epigenetic control, this work charts a promising roadmap for innovative treatment modalities aimed at overcoming therapeutic resistance in lung cancer.

Subject of Research:
Role of lactylation in lung cancer progression and drug resistance.

Article Title:
Not explicitly provided.

News Publication Date:
Not explicitly provided.

Web References:
http://dx.doi.org/10.1016/j.cmp.2026.03.004

Keywords:
Lung cancer, lactylation, epigenetics, metabolism, drug resistance, H3K18la, tumor immune escape, EGFR-TKIs, lactate signaling, histone modifications.